Astria Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Astria Therapeutics

12/08/2025 22:00

Astria Therapeutics Inc ATXS.OQ reported a quarterly adjusted loss of 57 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -43 cents.  The mean expectation of six analysts for the quarter was for a loss of 59 cents per share. Wall Street expected results to range from -67 cents to -51 cents per share.

Reported revenue was zero​; analysts expected zero.

Astria Therapeutics Inc's reported EPS for the quarter was a loss of 57 cents​.

The company reported a quarterly loss of $33.05 million.

Astria Therapeutics Inc shares had risen by 24.6% this quarter and lost 25.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 14.6% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Astria Therapeutics Inc is $29.00, about 77% above its last closing price of $6.68

This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.59
-0.57
Beat
Mar. 31 2025
-0.48
-0.58
Missed
Dec. 31 2024
-0.45
-0.20
Beat
Sep. 30 2024
-0.42
-0.42
Met